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News and Commentary
The esoteric roles of Bcl-2 family proteins in glucose
homeostasis and cell survival
S Pfeiffer1 and JHM Prehn*1
Cell Death and Disease (2015) 6, e1968; doi:10.1038/cddis.2015.320; published online 5 November 2015
The prevalence and the incidence of type 2 diabetes mellitus
(T2DM) are increasing and now attaining epidemic proportions
worldwide. Apoptotic cell death is a hallmark of pancreatic beta-
cell loss not only in type 1 diabetes mellitus (T1DM) but also in
all forms of diabetesmellitus, contributing to the development of
clinically overt disease.1,2 Although activation of pro-apoptotic
Bcl-2 protein family members Bax, Bim, Puma and Bad has
been identified to initiate beta-cell apoptosis in in vitro and
in vivo,3–5 recent years have seen the gradual elucidation of
additional roles played by Bcl-2 family proteins in the control of
beta-cell energetics and glucose-stimulated insulin secretion,
indicative of a role for Bcl-2 proteins in beta-cell physiology.6–8
In a recent study published in Cell Death Discovery,9 we not
only demonstrate a role for pro-apoptotic Bcl-2 homology
domain-3-only protein Bmf (Bcl-2-modifying factor) as
a mediator of beta-cell apoptosis in a mouse model of a
monogenic form of diabetes, HNF1α-MODY, but also reveal an
extracurricular role for Bmf in beta-cell insulin secretion unrelated
to cell death initiation in vivo (Figure 1). Hepatocyte nuclear
factor-1A maturity-onset diabetes of the young (HNF1α-MODY)
is the most common monogenic form of diabetes and is
characterized by a primary β-cell failure without features of
insulin resistance. The study follows on from previous work
demonstrating an AMP-activated protein kinase (AMPK)-depen-
dent induction of Bmf expression during energetic stress in
insulin-secreting cells and in the islets of transgenic mice
expressing a dominant-negative (DN) mutant of the transcription
factor HNF-1α in beta cells, identifying Bmfas a primarymediator
of beta-cell apoptosis in HNF1α-MODY.10 Through the introduc-
tion of bmf-deficiency in a transgenic HNF1α-MODY mouse
model, we report an attenuation in beta-cell loss and preserved
insulin content in bmf-deficient diabetic mice. Intriguingly, bmf-
deficiency was found to exacerbate rather than reduce
hyperglycemia and ultimately resulted in a decreased glucose-
stimulated insulin response, implicating a role for Bmf in glucose
homeostasis regulation in addition to effects on beta-cell survival.
Indeed, a decreased glucose-stimulated insulin response was
also observed in bmf-deficient non-MODY control mice.
This work expands on current re-thinking of the roles of
Bcl-2 family proteins and their functional involvement in
physiological pathways other than cell death and survival.11
Regulation of cellular metabolic functions in addition to
regulation of apoptosis in beta cells has previously been
observed in the case of the BH3-only protein Bad, which
regulates mitochondrial associated glucokinase activity and
mitochondrial respiration in beta cells.7 Anti-apoptotic Bcl-2
family proteins Bcl-2 and Bcl-xl have also been shown to
impact on mitochondrial nutrient metabolism and insulin
secretion signaling by dampening the beta-cell response to
glucose.6 This was observed in the absence of Bax and Bak
expression (indicating these were independent of apoptosis
signaling), and was attributed to effects of Bcl-xL and Bcl-2 on
ER and Ca2+ homeostasis. As both Bcl-2 and Bcl-xL regulate
mitochondrial fusion, effects of Bcl-2 and Bcl-xL on mitochon-
drial morphology, bioenergetics or quality control could have
likewise contributed. Bmf is capable of binding Bcl-2 and
Bcl-xL.12 In accordance with the observations of the Johnson
group, we demonstrate an impairment of glucose-stimulated
insulin secretion in bmf-deficient mice, and a resultant
aggravated hyperglycemia that was evident not only in
HNF1α-MODY mice but also in the control mice generated
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Figure 1 The dual roles for pro-apoptotic Bcl-2 homology domain-3-only protein
Bmf (Bcl-2-modifying factor) as a mediator of beta-cell apoptosis and beta-cell insulin
secretion in vivo: Bmf is required for glucose-stimulated insulin secretion in vivo,
thereby maintaining glycemic control (red arrow). Depletion of ATP and prolonged
activation of AMPK, however, also triggers Bmf-mediated apoptosis of beta cells,
resulting in decreased beta-cell mass and corresponding reduction in islet insulin
content (blue arrow)
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through a rigorous backcrossing strategy. Although the rat
insulin promoter (RIP) system targeted DNHNF-1α expression
to beta cells (and potentially other areas of the brain in which
HNF1α is not highly expressed), it should be noted that the bmf
knockout in this model resulted in gene deficiency in all tissues
potentially impacting on glucoregulation.
Interestingly, female mice in this model do not manifest the
same overt diabetic phenotype as male mice. The sexual
dimorphism observed in this model has been paralleled in
many other models of diabetes.13 Activation of estrogen
receptors in rodent models of T1DM and T2DM has been
shown to promote β-cell survival, indicating that the hormonal
profile of female animals appears to confer protection from the
development of overt diabetes.13,14 Interestingly, female mice,
that is, MODY mice were protected from beta-cell loss,
but were unprotected from loss of glucose-stimulated insulin
secretion upon deletion of bmf.
Taken together, the results of this study conclude that
deletion of bmf results in a rescue of the progressive beta-cell
death in a mouse model of monogenic diabetes, but
surprisingly also plays a role in glucose homeostasis with
an observable insulin secretory defect in vivo. This work
provides an insight into the ‘day-night’ dual role played by
Bmf and other BH3-only proteins in the control of in vivo
glucose homeostasis.
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